drugset / Trial / NCT00238277

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

NCT00238277 ↗

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide during and after radiation therapy may kill any tumor cells that remain after surgery and placement of Gliadel wafers. PURPOSE: This phase II trial is studying how well giving temozolomide during and after radiation therapy works in treating patients who have undergone previous surgery and placement of Gliadel wafers for newly diagnosed glioblastoma multiforme.

Timeline

Start
2005-02-15
Primary completion
2007-12-11
Completion
2007-12-11

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated - due to low accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule — Oral